DiaMedica Therapeutics, Inc. (DMAC)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about DiaMedica Therapeutics, Inc. (DMAC)
Go deeper and ask any question about DMAC
Company Performance
Current Price
as of Sep 13, 2024$4.50
P/E Ratio
N/A
Market Cap
$192.37M
Description
DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.
Metrics
Overview
- HQMinneapolis, MN
- SectorHealth Technology
- IndustryBiotechnology
- TickerDMAC
- Price$4.5+4.90%
Trading Information
- Market Cap$192.37M
- Float56.16%
- Average Daily Volume (1m)56,329
- Average Daily Volume (3m)71,660
- EPS-$0.52
Company
- RevenueN/A
- Rev Growth (1yr)N/A
- Net Income-$5.12M
- Gross MarginN/A
- EBITDA MarginN/A
- EBITDA-$5.63M
- EV$58.63M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
Documents
SEC Filings
Factset Street Account
Earnings Calls
Factset